Applied DNA and Spindle Biotech execute LOI

By The Science Advisory Board staff writers

March 15, 2022 -- Applied DNA Sciences and Spindle Biotech have executed a nonbinding letter of intent (LOI) that outlines the terms of a collaborative research agreement to bring together Applied DNA's LinearDNA platform and Spindle Biotech's proprietary, high yield RNA manufacturing system, the companies said in a press release.

Under the terms of the agreement, the companies will investigate the feasibility of using the LinearDNA platform to produce chemically modified DNA templates for use in Spindle Biotech's system. The companies hope for a simplified, high yield, and 100% cell-free workflow.

The use of LinearDNA as an IVT template removes several complex manufacturing steps necessitated by plasmid DNA, the companies said. Following initial validation work, the companies said they will explore the commercialization of an mRNA production system.

No financial details were disclosed.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.